about
Prognostic importance of defibrillator shocks in patients with heart failureQuality of life with defibrillator therapy or amiodarone in heart failureSurvival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).Quality of life effects of automatic external defibrillators in the home: results from the Home Automatic External Defibrillator Trial (HAT)Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.An entirely subcutaneous implantable cardioverter-defibrillator.Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure TrialOutcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac deathImplantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004.Key clinical insights from the sudden cardiac death in heart failure trial.Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.Absence of bilateral vision loss from amiodarone: a randomized trialRationale and design of the Home Automatic External Defibrillator Trial (HAT).Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.Thyroid function in heart failure and impact on mortality.Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias.Subcutaneous chronic implantable defibrillation systems in humans.Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II.Community-based automated external defibrillator only resuscitation for out-of-hospital cardiac arrest patients.Recent developments in the subcutaneous ICD.Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy.Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial.New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial.Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial.Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
P50
Q24631203-3277228E-CEF7-45A6-ACE0-D23188B909F1Q24646566-5FDA04D9-0DC1-4135-B7C3-159441F09E1FQ30589728-474C7355-1F2C-4507-ADC1-7E6C32FA8BC3Q30755342-D813D2D1-E2D8-4EA5-A18F-FBEB30D060D4Q30891180-B9141560-0B6E-43D0-8DAC-8C2D7FF8B163Q31106778-126AB62B-6155-4776-9B91-D0167F307310Q33156115-611DCBFE-D673-4F12-B4CF-9453A0FD34CEQ33248754-C2ACC54F-4A23-47C0-8E10-8DF2D83673FCQ33548994-5983F66B-F12D-432E-AF1C-FE55618225ADQ33786500-FC6D2F36-4428-4181-975F-A2365FD6DD88Q34069401-FA0D99ED-1E70-491E-A5F0-EA7B7B1C0747Q34069413-8A0CB145-631B-4AA6-BAD5-1A40BA489088Q34114976-9F8F1F9C-1980-4447-B6D7-DA6C8861BC28Q34194929-EB6922C1-8039-4799-9958-2C745383ACA0Q34237260-1A41C77E-BE69-4EFD-8D63-BEB64F2410E5Q34386004-20DCC795-8503-442F-BE18-DA4ED39D1A7EQ34441831-8AD00AD4-498E-4302-B7DA-09D3A212D8B4Q34633191-4BE20B86-AD57-420E-A82C-67572C0327AFQ36094817-40D82B3E-C450-4DCE-B8D4-EBFF31EBF6FBQ36173999-4689D6C1-DF2C-4D1D-BABF-A18C3007DDEEQ36733577-22019DC9-1223-459A-9E9F-FE95C47E7279Q36800828-8B7C5E62-D184-4A59-9D10-8B438AAAF4FBQ37000624-5301E04C-BC90-4D86-BC82-44D284586409Q37092356-B87A6352-AD5C-4221-B4E5-746CBBE267C3Q37100652-BDD5AC7D-E821-48D9-BB53-5C7F3235D57EQ37140509-A332091B-E13A-4B88-B459-ECEEA15F582CQ37176222-4145CBC6-F7B9-4CDC-AE67-CEECE7B6CA92Q37243900-CAEA09D5-5A8D-461E-879A-14475034A2F7Q37262628-26F87BD2-1A5E-49E9-9D05-F975D2EE4FCDQ37994562-3C11EE9A-7C41-49AC-A687-C63D8C9609DDQ38056298-6CA5156D-9682-4614-A9B4-F49B87571D71Q38660910-0F63B77D-8DA7-4C57-B190-CBD4A2AEE813Q38726256-D85FA689-1F36-403F-B1D5-DD2ACBBDA953Q38808632-94D7ADB3-AD80-4C44-AFE5-32E5D185353DQ41773480-9E484E97-6D9D-4F3F-8417-061D44B11F63Q42679144-4F506A67-5E89-4112-ABD4-66594038C054Q42689418-8EC3C790-3743-490E-9969-CED872CBE6A1Q43559149-2866FE1A-570E-4DCA-A304-4DDD0082F57EQ43858576-27E40A47-118F-4C64-BE22-7C3AD72ACD49Q43909512-992A16ED-FB59-49F1-A8FD-E23F09E86DDA
P50
name
Gust H Bardy
@ast
Gust H Bardy
@en
Gust H Bardy
@nl
type
label
Gust H Bardy
@ast
Gust H Bardy
@en
Gust H Bardy
@nl
prefLabel
Gust H Bardy
@ast
Gust H Bardy
@en
Gust H Bardy
@nl